%0 Journal Article
%T The evolving landscape of predictive biomarkers of response to PARP inhibitors
%A Anish Thomas
%A Junko Murai
%A Yves Pommier
%J The Journal of Clinical Investigation
%D 2018
%R 10.1172/JCI120388
%X Poly(ADP-ribose) polymerase inhibitors (PARPis) are DNA-damaging agents that trap PARP-DNA complexes and interfere with DNA replication. Three PARPis ¡ª olaparib, niraparib, and rucaparib ¡ª were recently approved by the FDA for the treatment of breast and ovarian cancers. These PARPis, along with 2 others (talazoparib and veliparib), are being evaluated for their potential to treat additional malignancies, including prostate cancers. While lack of PARP-1 confers high resistance to PARPis, it has not been established whether or not the levels of PARP-1 directly correlate with tumor response. In this issue of the JCI, Makvandi and coworkers describe an approach to address this question using [18F]FluorThanatrace, an [18F]-labeled PARP-1 inhibitor, for PET. The tracer was taken up by patient tumor tissue and appeared to differentiate levels of PARP-1 expression; however, future studies should be aimed at determining if this tracer can be used to stratify patient response to PARPi therapy
%U https://www.jci.org/articles/view/120388